A phase II trial of GTP-004 in Myasthenia Gravis patients
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2018
Price : $35 *
At a glance
- Drugs Ondansetron/pyridostigmine (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 26 Mar 2018 According to a GT Biopharma media release, based on additional data from phase 1 study the company expects to potentially accelerate the start of its Phase 2 trial in MG patients to the third quarter of 2018.
- 29 Jan 2018 New trial record
- 24 Jan 2018 According to a GT Biopharma media release, this trial is expected to begin in the second half of 2018.